All In Biotech

NDA 205836 · Ucb INC

Briviact

Brivaracetam · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Aug 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Feb 18, 2016

Approved uses

4

Original approval plus efficacy supplements

Registered trials

52

27 Phase 3, 0 recruiting

FAERS reports

9,327

7,450 serious, 467 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 5, 2026.

BRIVIACT is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. BRIVIACT is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. ( 1 )

Mechanism: The precise mechanism by which BRIVIACT exerts its anticonvulsant activity is not known. Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain, which may contribute to the anticonvulsant effect.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • BRIVIACT · BRIVARACETAM 75MG · TABLET, ORAL · Prescription · TE AB
  • BRIVIACT · BRIVARACETAM 25MG · TABLET, ORAL · Prescription · TE AB
  • BRIVIACT · BRIVARACETAM 100MG · TABLET, ORAL · Prescription · TE AB
  • BRIVIACT · BRIVARACETAM 50MG · TABLET, ORAL · Prescription · TE AB
  • BRIVIACT · BRIVARACETAM 10MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Brivaracetam" as an intervention, any sponsor and status, largest first.

All 52 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure3,353
  • off label use1,195
  • drug ineffective1,051
  • fatigue600
  • therapy interrupted545
  • somnolence532
  • overdose516
  • dizziness479
  • product availability issue403
  • fall381
  • generalised tonic-clonic seizure360
  • epilepsy352

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
20121
20142
20155
2016107
2017231
2018435
2019773
2020692
2021931
20221,034
20231,205
20241,261
20251,396
20261,253

Recalls

1 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Briviact* (Brivaracetam)

2024 spending

$220M

Beneficiaries

15,497

137,123 claims

Per beneficiary

$14,182

$23.38 per unit

View as table
YearSpending
2020$97,878,890
2021$119,191,699
2022$149,528,079
2023$184,375,922
2024$219,770,911

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 134 on PubMed

Sponsor: UCB

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.